APGE
Apogee Therapeutics, Inc.
$133.54
+0.04 (+0.03%)
At close · Jul 7
Market Cap
$10.07B
Shares
75,389,375
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$133.54
Open$133.30
Day$133.27–133.87
52W$34.34–133.87
Avg vol 30d4.4M
Short int10.5M · 13.9% float · 10.3d
Short vol29%
Last earningsMay 27, 2026
DataJul 2023–Jul 2026
Filing10-Q · May 11
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+79% above
+
Price vs 50-day avg
+42% above
−
RSI (14)
81 · overbought
+
MACD trend
positive
+
52-week position
100% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $94 › 200d $75 — 50d above 200d
+
Institutional flow
3 of 229 funds reported for Jun 30 · net +102 sh shares · +1 new
−
Insider flow
Net -$4.5M over 90 days · 100% sells
+
Short interest
13.90% of float · ▼ -0.5% MoM · 10.3 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
229 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−28% Y/Y
−
Free cash flow
$-232.6M
+
Balance sheet
net cash $131.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 26, 2026
Est · unconfirmed
· in 7 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+79% above
Bullish
Price vs 50-day avg
+42% above
Bullish
RSI (14)
81 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
100% · near high
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $94 › 200d $75 — 50d above 200d
Institutional flow
Accumulating
3 of 229 funds reported for Jun 30 · net +102 sh shares · +1 new
Insider flow
Distributing
Net -$4.5M over 90 days · 100% sells
Short interest
Falling
13.90% of float · ▼ -0.5% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
229 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $34
Now $134 · 100%
52-wk high $134
vs 200-day avg +79%
vs 50-day avg +42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APGE
this stock
Apogee Therapeutics, Inc.
|
$10.07B | +76.9% | — | — | 13.9% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APGE | +0.7% | +53.6% | +72.0% | +0.6% | +76.9% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -0.2% | +52.3% | +64.4% | +0.5% | +67.3% |